Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of EMB-01 plus osimertinib in advanced or metastatic EGFR-mutant non-small cell lung cancer
CTR20222428Phase 2Active
- Sponsor
- EpimAb Biotherapeutics
- Start
- Sep 2022
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of emb-01, osimertinib in non-small cell lung cancer (NSCLC), sponsored by EpimAb Biotherapeutics. Started Sep 2022; status: active.
02
Drugs
emb-01osimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222428.